A recent phase I/II trial evaluated a combination of tumor-targeting interleukin 12 antibody-drug conjugate (PDS01ADC), the bifunctional anti-programmed cell death ligand 1 (PD-L1)/transforming growth factor β (TGF-β) bintrafusp alfa, and the HPV 16 therapeutic vaccine (PDS0101) for clinical activity in adult patients with HPV 16-associated cancers. The gene discussed is CD274; the disease is neoplasm.